New protein drug trial produces promising safety results for rare pulmonary condition

INBRX-101 is engineered to maximize the functional activity of AAT, particularly in the lung. Credit: UC Davis A multicenter safety study at UC Davis Health tested a protein drug (INBRX-101), developed to improve care for people with alpha-1 antitrypsin deficiency (AATD), and showed the therapy is quite safe. Published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, these results are good news for patients with AATD. This trial also sets the stage for a pivotal phase 2/3 trial, which will assess the drug’s efficacy and possibly lead Read More

Related posts:

  1. Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use
  2. Study suggests ISM1 protein may have protective role in resisting pulmonary fibrosis
  3. New simple test detects rare fatal genetic heart condition
  4. Gene therapy halts progression of rare genetic condition in young boy
  5. Researchers discuss cellular inflammation uncovered in rare neurodegenerative condition
  6. Promising pathway discovered to treat rare childhood brain disease
  7. Successful trial for new colorectal cancer treatment highlights promising immunotherapy drugs
  8. Clinical trial reports promising new treatment reduces suffering in Sanfilippo syndrome

Leave a Reply

Your email address will not be published. Required fields are marked *